Simulations Plus, INC 8-K filings

Simulations Plus announced third quarter fiscal 2026 financial results, showing a 7% increase in total revenue driven by services, and confirmed a definitive merger agreement to be acquired by Altaris, LLC.

Simulations Plus, Inc. has entered into a definitive agreement to be acquired by Altaris, LLC for $18.50 per share in cash, valuing the company at approximately $18.50 per share.

Simulations Plus, Inc. announced a definitive agreement to be acquired by Altaris, LLC in an all-cash transaction for approximately $375 million, with stockholders to receive $18.50 per share.

Simulations Plus announced its second quarter fiscal 2026 financial results, reporting an 8% increase in total revenue to $24.3 million, driven by growth in both software and services.

Simulations Plus reported a 3% total revenue decrease to $18.4 million for Q1 fiscal 2026, driven by a 17% decline in software revenue, despite a 16% increase in services revenue.

Simulations Plus, Inc. has entered into new and amended employment agreements with seven key executives, detailing updated compensation structures and severance terms.

Simulations Plus reported a 6% revenue decrease in Q4 2025 and a significant full-year net loss of $64.7 million due to an impairment charge, while reaffirming fiscal 2026 revenue guidance.

Simulations Plus announced preliminary fiscal year 2025 results, meeting revised guidance, and issued conservative fiscal year 2026 guidance amidst a challenging market.

Simulations Plus, Inc. has dismissed Grant Thornton LLP as its independent auditor, citing challenges in finalizing segment reporting and internal controls, a move Grant Thornton disputes, stating these matters were unresolved to their satisfaction.

Simulations Plus, Inc. reported a significant net loss of $67.3 million for its third fiscal quarter ended May 31, 2025, primarily due to a $77.2 million non-cash impairment charge, while revenue grew 10% and adjusted diluted EPS increased to $0.45.

Simulations Plus, Inc. has rescheduled its third quarter fiscal 2025 earnings release and conference call to July 14-15, 2025, citing its transition to a non-accelerated filer status, while reaffirming its preliminary Q3 and full-year 2025 revenue guidance.

Simulations Plus, Inc. announced preliminary third-quarter fiscal 2025 revenue and updated its full-year 2025 revenue guidance, citing significant market uncertainties and headwinds impacting client budgets and services demand.

Simulations Plus, Inc. announced preliminary third-quarter fiscal 2025 revenue and updated its full-year fiscal 2025 revenue guidance downwards, citing significant market uncertainties impacting its biopharma clients.

Simulations Plus, Inc. announced a significant reorganization of its executive leadership team and a 10% workforce reduction, aiming to streamline operations and achieve $4.3 million in annualized cost savings.

Simulations Plus has dismissed Rose, Snyder & Jacobs LLC and appointed Grant Thornton LLP as its new independent registered public accounting firm, effective immediately.

Simulations Plus announces a 23% year-over-year increase in total revenue for Q2 2025, driven by growth in both software and services, while maintaining full-year revenue guidance.

Simulations Plus successfully held its 2025 Annual Meeting of Shareholders, electing directors and ratifying the company's independent auditor.

Simulations Plus reported a 31% year-over-year increase in total revenue for the first quarter of fiscal year 2025, primarily driven by strong software growth.

Simulations Plus announced an 18% increase in fiscal year 2024 revenue to $70 million and provided a strong revenue growth outlook for fiscal year 2025.

Simulations Plus announced a restructuring of its business units and leadership team to optimize growth following recent acquisitions, including the departure of two key executives.

Simulations Plus announced a 14% increase in total revenue for the third quarter of fiscal year 2024, reaching $18.5 million, while maintaining full-year revenue guidance.

Simulations Plus has acquired Pro-ficiency for $100 million in cash, creating a comprehensive platform spanning the drug development continuum from pre-clinical to commercialization.

Simulations Plus presented at the BTIG investor conference, showcasing its leadership in biosimulation, strong financial performance, and strategic growth plans.

Simulations Plus announced a 16% increase in total revenue to $18.3 million and diluted earnings per share of $0.20 for the second quarter of fiscal year 2024, while reaffirming its full-year revenue and EPS guidance.

Simulations Plus presented at the Oppenheimer investor conference, showcasing its leadership in biosimulation and its growth strategy.

Simulations Plus shareholders approved an increase in the number of shares authorized for issuance under the 2021 Equity Incentive Plan from 1,550,000 to 2,500,000 at the annual meeting on February 8, 2024.